Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Romosozumab binds to and inhibits sclerostin, promoting the activation of the Wnt/_-catenin pathway that normally stimulates osteoblasts.